



Tau2020 Global Conference
Feb. 12-13, 2020
Marriott Marquis, Washington, D.C.

Wednesday, Feb. 12

7:30-8:15 a.m. **Breakfast**

8:30-8:45 a.m. **Welcome Remarks**

Hosts:

Alzheimer's Association, Harry Johns, MBA

CurePSP, Larry Golbe, M.D.

Rainwater Charitable Foundation, Patrick Brannelly, MBA

Tau 2020 Co-Chairs:

Diana Kerwin, M.D. and Peter Davies, Ph.D.

8:45-8:50 a.m. **First Plenary Introduction**

Luc Buée, Ph.D.

8:50-9:20 a.m. **First Plenary**

Tau Research: History and Current Challenges

Jean-Pierre Brion, M.D., Ph.D.

Session 1:

Tauopathies

9:20-9:40 a.m. **Tau and Neurodegeneration**

Maria Grazia Spillantini, Ph.D.

9:40-10 a.m. **NPC/Other Secondary Tauopathies**

Marc Patterson, M.D.

10-10:20 a.m. **Plenary and Panel Discussion**

Moderator: Irene Litvan, M.D.

10:20-10:45 a.m. **Break**

Session 2:

Tau Imaging

10:45-11:05 a.m. **Overview of Tau Imaging in Aging and AD**

Keith Johnson, M.D.

11:05-11:25 a.m. **Tau Imaging in Non AD Tauopathies**

Gil Rabinovici, M.D.

11:25-11:45 a.m. **Taupography: What Does It Tell Us?**

Gael Chetelat, M.D., Ph.D.

11:45 a.m.- **Tau Imaging in Anti-Tau Clinical Trials:**

Kristin Wildsmith, Ph.D.

12:05 p.m. **[¹⁸F]GTP1 and the Semorinemab Biomarker Strategy**

12:05-12:30 p.m. **Panel Discussion**

Moderator: Margaret Sutherland, Ph.D.

12:30-1:45 p.m. **Lunch and Poster Viewing**

- 1:45-2:45 p.m. **Lightning Poster Session**
Moderator: Luc Buée, Ph.D.
- 2:45-2:50 p.m. **Second Plenary Introduction** **Kathryn Bowles, Ph.D.**
- 2:50-3:20 p.m. **Second Plenary**
What Genetic and Functional Studies
Have Taught Us About the Role of
MAPT in Neurodegeneration? **Alison Goate, D. Phil.**
- Session 3: Genetics and Tauopathies**
- 3:20-3:40 p.m. Molecular Drivers of Primary Tauopathy
- 3:40-4:05 p.m. Common Genetic Features in Primary
Tauopathies **Celeste Karch, Ph.D.**
John Hardy, Ph.D. &
Huw Morris, M.D., Ph.D.
- 4:05-4:25 p.m. Tau Contributions to Cognitive Decline in
Neurodegenerative Diseases: Lessons From
Colombian Families With Autosomal-Dominant
Mutations **Yakeel Quiroz, Ph.D.**
- 4:25-4:45 p.m. **Plenary and Panel Discussion**
Moderator: Jennifer Yokoyama, Ph.D.
- 4:45-5:10 p.m. **Break**
- 5:10-5:25p.m. Open AD: Open Science and Drug Discovery **Aled Edwards, Ph.D.**
- 5:25-6:05 p.m. **Panel and Debate**
Moderator: Martin Citron, Ph.D.
- Propagation: Do We Have Sufficient Evidence? If Not, What Next?**
- Sufficient Evidence: Marc Diamond, M.D. & Bess Frost, Ph.D.**
Insufficient Evidence: Karen Duff, Ph.D. & Brad Hyman, M.D., Ph.D.
- 6:05-6:35 p.m. **Lightning Rounds for CurePSP**
Moderator: Larry Golbe, M.D.
- 6:35-6:40 p.m. **Close of Day One**
Maria Carrillo, Ph.D.
- 6:45-9 p.m. **Rainwater Prize Reception and Buffet**
All are welcome

Thursday, Feb. 13

7:30-8:30 a.m.	Breakfast	
8:30-8:45 a.m.	Open of Day Two	Maria Carrillo, Ph.D.
Session 4:	Molecular Mechanism for Therapeutic Approaches	
8:45-9:05 a.m.	Routing Tau Between and Within Cells	Kenneth S. Kosik, M.D.
9:05-9:25 a.m.	Exploring the Biodistribution of Tau-Targeting BBB-Penetrant Fusion Proteins in the CNS	Sarah DeVos, Ph.D.
9:25-9:45 a.m.	Progress and Challenges Advancing the National Plan to Address AD/ADRD	Eliezer Masliah, M.D.
9:45-10:05 a.m.	Discovery of Brain Penetrant PROTAC® Degradation Molecules That Target Pathologic Tau	Angela Cacace, Ph.D.
10:05-10:25 a.m.	Panel Discussion Moderator: Mike Hutton, Ph.D.	
10:25-10:55 a.m.	Break and Checkout	
10:55-11:55 a.m.	Second Lightning Poster Session Moderator: Hui Zheng, Ph.D.	
11:55 a.m.- 12:55p.m.	Rainwater Prize Ceremony Keynote: Walter Koroshetz, M.D. Short Talks: Patrick Hsu, Ph.D. and Michel Goedert, M.D., Ph.D.	
12:55-2:10 p.m.	Lunch and Poster Viewing	
2:10-2:15 p.m.	Third Plenary Introduction	Diana Kerwin, M.D.
2:15-2:45 p.m.	Third Plenary Tau Therapeutics: Translational Challenges in Moving From Bench to Bedside	Adam Boxer, M.D., Ph.D.
Session 5:	Tau Therapeutics	
2:45-3:05 p.m.	RNA-Targeted Therapy for Tauopathies	Timothy Miller, M.D., Ph.D.
3:05-3:25 p.m.	Initial Results From a Phase 2 Study of the Pan-Tau Antibody 8E12 in Patients With Progressive Supranuclear Palsy	Mike Gold, M.D.
3:25-3:45 p.m.	Targeting Tau In AD: A Trialist's Perspective	Cath Mummery, M.D., Ph.D.
3:45-4:05 p.m.	Industry Perspective	Philipp von Rosentiel, M.D.

- 4:05-4:25 p.m. **Plenary and Panel Discussion**
Moderator: Howard Feldman, M.D.
- 4:25-4:40 p.m. **Break**
- 4:40-5:15 p.m. **Panel Session**
Early Stage Investment in Tau Therapeutics
Moderator: Patrick Brannelly, MBA
Stacie Weninger, Ph.D.
James Mutamba, Ph.D.
Dirk Beher, Ph.D.
- 5:15-5:30 p.m. **Closing Remarks**
Co-Chairs:
Drs. Peter Davies and Diana Kerwin